Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors

被引:68
作者
Hindson, Benjamin R. [1 ,2 ]
Millar, Jeremy L. [1 ,3 ]
Matheson, Bronwyn [1 ,2 ]
机构
[1] Alfred Hlth, William Buckland Radiat Oncol, Melbourne, Vic 3004, Australia
[2] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia
[3] Monash Univ, Dept Epidemiol & Preventat Med, Melbourne, Vic 3004, Australia
关键词
Prostate cancer; High-dose-rate brachytherapy; Urethral stricture; Late toxicity; CONFORMAL RADIATION-THERAPY; EXTERNAL-BEAM RADIOTHERAPY; HDR BRACHYTHERAPY; RANDOMIZED-TRIAL; ESCALATION; BOOST;
D O I
10.1016/j.brachy.2012.03.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: High-dose-rate brachytherapy is an established technique to deliver a conformal dose of radiation to patients with prostate cancer. The William Buckland Radiotherapy Center has been performing high-dose-rate brachytherapy with external beam radiation treatment for prostate cancer since 1998 and has an extensive prospective database on all patients treated. The purpose of this analysis was to assess the risk of stricture formation and identify the predictive or causative factors. METHODS AND MATERIALS: Three hundred fifty-four patients were treated between 1998 and 2008. Patients received one of three differing dose schedules: 20 Gy in four treatments (20 Gy/4), 18 Gy/3, and 19 Gy/2 during three sequential time periods. Nelson-Aalen cumulative hazard modeling was used to estimate risk of events over time. Potential risk factors, including dose, were identified and used in the analysis. RESULTS: There were 45 patients who developed at least one stricture, an overall risk of 8.2% at 2 years. The 2-year risk of stricture formation was 3.4%, 2.3%, and 31.6% for 18 Gy/3, 20 Gy/4, and 19 Gy/2, respectively. Most strictures occurred in the bulbomembranous urethra (50%) or external sphincter region (33%). On multivariable analysis, the dose schedule used was the only significant predictor for increased stricture formation. CONCLUSIONS: In our patients, those who received 19 Gy/2 were at a significantly higher risk of stricture formation. Most of these, strictures were mild, requiring only one intervention but a 2-year stricture risk of 31.6% was striking, and we have modified our protocol. (C) 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:50 / 55
页数:6
相关论文
共 26 条
[1]  
[Anonymous], 2010, Common Terminology Criteria for Adverse Events (CTCAE) v4.0
[2]   Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer [J].
Åström, L ;
Pedersen, D ;
Mercke, C ;
Holmäng, S ;
Johansson, KA .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (02) :157-161
[3]   AN EIGHT-YEAR EXPERIENCE OF HDR BRACHYTHERAPY BOOST FOR LOCALIZED PROSTATE CANCER: BIOPSY AND PSA OUTCOME [J].
Bachand, Francois ;
Martin, Andre-Guy ;
Beaulieu, Luc ;
Harel, Frantcois ;
Vigneault, Eric .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :679-684
[4]   Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial [J].
Dearnaley, David P. ;
Sydes, Matthew R. ;
Graham, John D. ;
Aird, Edwin G. ;
Bottomley, David ;
Cowan, Richard A. ;
Huddart, Robert A. ;
Jose, Chakiath C. ;
Matthews, John H. L. ;
Millar, Jeremy ;
Moore, A. Rollo ;
Morgan, Rachel C. ;
Russell, J. Martin ;
Scrase, Christopher D. ;
Stephens, Richard J. ;
Syndikus, Isabel ;
Parmar, Mahesh K. B. .
LANCET ONCOLOGY, 2007, 8 (06) :475-487
[5]   High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer [J].
Deger, S ;
Boehmer, D ;
Roigas, J ;
Schink, T ;
Wernecke, KD ;
Wiegel, T ;
Hinkelbein, W ;
Budach, V ;
Loening, SA .
EUROPEAN UROLOGY, 2005, 47 (04) :441-448
[6]   High dose rate brachytherapy of localized prostate cancer [J].
Deger, S ;
Boehmer, D ;
Türk, I ;
Roigas, J ;
Wernecke, KD ;
Wiegel, T ;
Hinkelbein, W ;
Dinges, S ;
Budach, V ;
Loening, SA .
EUROPEAN UROLOGY, 2002, 41 (04) :420-426
[7]   Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE [J].
Elliott, Sean P. ;
Meng, Maxwell V. ;
Elkin, Eric P. ;
McAninch, Jack W. ;
Duchane, Janeen ;
Carroll, Peter R. .
JOURNAL OF UROLOGY, 2007, 178 (02) :529-534
[8]   Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer [J].
Galalae, RM ;
Kovács, G ;
Schultze, J ;
Loch, T ;
Rzehak, P ;
Wilhelm, R ;
Bertermann, H ;
Buschbeck, B ;
Kohr, P ;
Kimmig, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01) :81-90
[9]   High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds [J].
Grills, IS ;
Martinez, AA ;
Hollander, M ;
Huang, RW ;
Goldman, K ;
Chen, PY ;
Gustafson, GS .
JOURNAL OF UROLOGY, 2004, 171 (03) :1098-1104
[10]   High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial [J].
Hoskin, Peter J. ;
Motohashi, Kate ;
Bownes, Peter ;
Bryant, Linda ;
Ostler, Peter .
RADIOTHERAPY AND ONCOLOGY, 2007, 84 (02) :114-120